Oral Abstract Session
New IgAN Therapies: Subgroups, Outcomes, and Biomarkers
October 23, 2026 | 04:30 PM - 06:00 PM
Location: Room 501, Convention Center
Session Description
Oral Abstract Session
Learning Pathway(s)
- Glomerular Diseases
Moderators
Presentations
Zigakibart Results in Sustained Proteinuria Reduction and Remission Through 124 Weeks of Treatment in Patients with IgAN
Effect of Iptacopan on Complement and Inflammatory Biomarkers in IgAN: Final 24-Month Results of the Phase 3 APPLAUSE-IgAN Study
Proteinuria-Reducing Effect of Sparsentan in Japanese Pediatric and Adult Patients with IgAN: Interim Analysis at Week 36
Natural History of Recurrent IgAN After Kidney Transplantation: Findings from the UK National Registry of Rare Kidney Diseases (RaDaR)
Extended Nefecon Therapy for Residual Proteinuria in Primary IgAN: A Propensity Score-Matched Real-World Study
Urinary Biomarker Data from the PROTECT Study in IgAN Demonstrate Renal Anti-Inflammatory Actions of Sparsentan, Including Reduced Macrophage, Complement, and B-Cell Activation Signals
Efficacy and Safety of Telitacicept in IgAN with Crescents
Efficacy and Safety of Extended Nefecon Therapy in IgAN: A Real-World Retrospective Study
Effect of Sparsentan on Urine and Plasma Proteome of Patients with IgAN: Findings from the SPARTAN Study